Table 2 Transplant characteristics
Transplant characteristics | RIC | MAC | p value |
|---|---|---|---|
Number of patients | 271 | 425 | Â |
Source of stem cells | 0.001 | ||
 BM | 95 (35.1 %) | 202 (47.5 %) |  |
 PB | 176 (64.9 %) | 223 (52.5 %) |  |
Conditioning regimen | Â | ||
 Chemotherapy-based | 200 (73.8 %) | 306 (72 %) |  |
 TBI-based | 71 (26.2 %) | 119 (28 %) |  |
In vivo T depletion | 0.26 | ||
 Yes | 140 (51.7 %) | 201 (47.3 %) |  |
 Thymoglobulin | 127 (91 %) | 185 (92 %) | |
 Lymphoglobulin | 2 (1 %) | 1 (0.5 %) |  |
 Alemtuzumab | 11 (8 %) | 15 (7.5 %) |  |
 No | 131 (48.3 %) | 224 (52.7 %) | |
Post-transplant GVHD prophylaxis | <0.0001 | ||
 CsA/FK506 + MMF or MTX | 61 (23.2 %) | 120 (30.3 %) |  |
 CsA + MMF + MTX | 2 (0.8 %) | 55 (13.9 %) |  |
 CsA + MMF + MTX + Basiliximab | 19 (7.2 %) | 40 (10.1 %) |  |
 PT-Cy + CsA/FK506 + MMF | 66 (25.1 %) | 125 (31.6 %) |  |
 Sirolimus + MMF | 87 (33.1 %) | 10 (2.5 %) |  |
 Other | 28 (10.6 %) | 46 (11.6 %) |  |
DLI | Â | Â | NS |
 No DLI | 247 (91.1 %) | 389 (92.5 %) |  |
 Pre-emptive DLI | 11 (4.1 %) | 14 (3.3 %) |  |
 DLI after relapse | 13 (4.8 %) | 22 (5.2 %) |  |